ArticleDiscover oncology2026
Single-cell and immune-context integration identifies basement-membrane/metastasis signatures that sharpen bladder-cancer diagnosis and prognosis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer(BLCA) has a high recurrence rate and metastasis, and its process is closely related to basement membrane remodeling. we developed an interpretable prognostic model based on metastasis-basement membrane-related genes (MBRGs) to enhance clinical and personalized treatment strategies.
methodDifferentially expressed MBRGs from TCGA and GEO cohorts were analyzed. Prognostic genes were identified by univariate Cox and LASSO regression. A six-MBRG risk model was built and externally validated. SHAP analysis quantified feature contributions. Functional enrichment analyzed via GSEA and KEGG. Immune cell profiles estimated with CIBERSORT and ssGSEA. Immunotherapy response predicted using TMB, TIDE, and mutation frequency. Single-cell and spatial transcriptomics localized key genes to cancer-associated fibroblasts(CAFs).
resultsThrough analysis of metastasis and basement membrane-associated DEGs, 18 candidate MBRGs were identified and refined via univariate Cox and SHAP to a 6-gene signature (SERPINF1, DDR2, SLIT2, HSPG2, ECM1, RECK). This signature demonstrated prognostic power with AUCs of 0.638-0.674 in TCGA and 0.602-0.742 in GEO cohorts. A clinical nomogram achieved an AUC of 0.827. The high-risk group exhibited elevated M2 macrophages and TIDE scores(a computational metric for predicting tumor immune evasion and immunotherapy response), whereas the low-risk group showed enriched CD8⁺ T cells. Drug assays indicated dasatinib sensitivity in low-risk patients, and LGK974, LY2109761, and Wnt-C59 in high-risk patients. Single-cell RNA-seq and IHC confirmed CAF-specific overexpression of DDR2 and SERPINF1.
conclusionThe MBRG-based model effectively predicts BLCA prognosis, integrates mechanisms of basement membrane remodeling, EMT, and immune suppression, and identifies DDR2 and SERPINF1 in CAFs as potential targets for personalized therapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.